Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (COPD), casting a shadow over the programme. On the ...
Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the company has now lined up what looks like an impressive successor. The pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback